Virtual Reality Distraction for Reduction

Sponsor
The Cleveland Clinic (Other)
Overall Status
Recruiting
CT.gov ID
NCT04416555
Collaborator
(none)
113
1
2
28.9
3.9

Study Details

Study Description

Brief Summary

Using a randomized controlled design, the investigators goal is to estimate the effect of VR on postoperative analgesia and opioid consumption.

Condition or Disease Intervention/Treatment Phase
  • Device: Placebo comparator: VR googles and the non reality experience
  • Device: Active Comparator: VR googles and the real VR program to enter act with and experience
N/A

Detailed Description

Specifically, the investigators propose to test the primary hypothesis that the use of AppliedVR software in Pico G2 4K headsets decreases acute postoperative pain scores (with a 1 point difference considered clinically important) compared to sham treatment on a 0-10 scale 15 minutes after each use in the first 48 hours after surgery or hospital discharge, whichever comes first.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
113 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Intervention Model Description:
parallel assignment (one arm will receive the full immersive virtual reality experience and the other arm will receive a static presentation in the same device)parallel assignment (one arm will receive the full immersive virtual reality experience and the other arm will receive a static presentation in the same device)
Masking:
Double (Participant, Outcomes Assessor)
Masking Description:
Single (Outcomes Assessor)
Primary Purpose:
Supportive Care
Official Title:
Virtual Reality Distraction for Reduction in Acute Postoperative Pain
Actual Study Start Date :
Aug 3, 2020
Anticipated Primary Completion Date :
Aug 30, 2022
Anticipated Study Completion Date :
Dec 30, 2022

Arms and Interventions

Arm Intervention/Treatment
Placebo Comparator: VR googles using exposure sham program

The study groups will receive VR googles and the sham program

Device: Placebo comparator: VR googles and the non reality experience
parallel assignment (this arm will receive a static presentation in the same device)

Active Comparator: VR googles and the real VR program experience.

The study group will receive the VR googles and the real VR program experience.

Device: Active Comparator: VR googles and the real VR program to enter act with and experience
Parallel assignment (this arm will receive the full immersive virtual reality experience

Outcome Measures

Primary Outcome Measures

  1. Pain Scores [From the end of surgery until 48 hours after surgery or discharge, whichever comes first]

    The investigators will assess pain using NRS scores (0-10, with 10 being worst)

Secondary Outcome Measures

  1. Total opioid consumption [Within the first 72 hours.]

    the investigators will measure total opioid consumption converted to morphine milligram equivalents (MME).

  2. Time weighted average pain score [Every 4 hours by standard of care during the first 48 hours after surgery or hospital discharge, whichever comes first using NRS scores (0-10, with 10 being worst).]

    The investigators will capture all pain scores measurements

  3. Perception of video system usability [Once after the last assessment or hospital discharge, whichever comes first.]

    Patient's perception of video system usability will be assessed using a validated questionnaire (System Usability Scale). The System Usability Scale is scored from 0 to 100 and higher scores are related with devices that are easier to use.

  4. Post discharge analgesia. [One week (7days) after hospital discharge]

    Pain Outcomes Questionnaire Short Form, which evaluates five domains (pain, mobility, activities of daily living, vitality, negative affect and fear). The Pain Outcomes Questionnaire Short Form is scored from 0 to 190 and higher scores are related with worst pain outcomes.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 85 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • American Society of Anesthesiology Physical Status 1-3;

  • Scheduled for elective, primary total hip arthroplasty;

  • Anticipated hospitalization of at least 1 night;

  • Expected to require parenteral opioids for postoperative pain;

  • Able to use IV PCA systems.

Exclusion criteria:
  • History of chronic pain or care by a pain management specialist;

  • Use of more than 30 mg/day of oral oxycodone (or equivalent);

  • Greater than 12 weeks of current and continued opioid use;

  • History of seizures, epilepsy, motion sickness, stroke, dementia;

  • Non-English speaking;

  • Women who are pregnant or breastfeeding;

  • History of substance use disorder.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Cleveland Clinic Fairview Hospital Cleveland Ohio United States 44111

Sponsors and Collaborators

  • The Cleveland Clinic

Investigators

  • Principal Investigator: Sabry Ayad, MD, The Cleveland Clinic

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
The Cleveland Clinic
ClinicalTrials.gov Identifier:
NCT04416555
Other Study ID Numbers:
  • 19-769
First Posted:
Jun 4, 2020
Last Update Posted:
Jan 11, 2022
Last Verified:
Jan 1, 2022
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
Yes
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jan 11, 2022